Successful Treatment of Recalcitrant Subcorneal Pustular Dermatosis (Sneddon-Wilkinson Diseases) With Apremilast
Keywords:
Sneddon-Wilkinson disease, subcorneal pustular dermatosis, neutrophilic dermatosis, apremilastReferences
Cheng S, Edmonds E, Ben-Gashir M, Yu RC. Subcorneal pustular dermatosis: 50 years on. Clin Exp Dermatol. 2008;33(3):229-233. DOI:10.1111/j.1365-2230.2008.02706.x. PMID: 18355359.
Teraki Y, Sugai S. Treatment of recalcitrant subcorneal pustular dermatosis with guselkumab. Int J Dermatol. 2021;60(4):e153-e154. DOI:10.1111/ijd.15311. PMID: 33226124.
Magdaleno-Tapial J, Valenzuela-Oñate C, Alonso-Carpio M, et al. Improvement of recalcitrant Sneddon-Wilkinson disease with apremilast. Australas J Dermatol. 2020;61(2):185-186. DOI:10.1111/ajd.13253. PMID: 32048271.
Maione V, Bettolini L, Venturuzzo A, Tonon F, Battocchio S, Calzavara-Pinton P. Efficacy of apremilast in a case of resistant linear IgA bullous disease. Int J Dermatol. 2023;62(5):e300-e302. DOI:10.1111/ijd.16548. PMID: 36468775.
Schett G, Sloan VS, Stevens RM, Schafer P. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis. 2010;2(5):271-278. DOI:10.1177/1759720X10381432. PMID: 22870453. PMCID: PMC3383510.
Published
Issue
Section
License
Copyright (c) 2023 Luca Bettolini, Stefano Bighetti, Paolo Incardona, Piergiacomo Calzavara-Pinton, Vincenzo Maione
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.